Maaike S.
- Country
- The Netherlands
- Department
- Afd. Interne geneeskunde
Research Overview
- Phase 3 Randomized Study of JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After Prior PI, IMiD, and Anti-CD38 Therapy
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- Phase 3 Evaluation of Teclistamab with Lenalidomide versus Lenalidomide Monotherapy in Maintenance Therapy for Newly Diagnosed Multiple Myeloma Post-ASCT
Data & Insights
Has run more than one trial at 223 of 418 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndromes, with particular emphasis on innovative therapeutic approaches for newly diagnosed patients.
- Blood Cancer Management
- Hematologic Malignancies
- Bone Marrow Disorders
The investigator's work encompasses the evaluation of novel treatment combinations for blood disorders.
Treatment Innovation
Focus areas include developing targeted therapies using venetoclax-based combinations for hematologic conditions, particularly in the context of induction and consolidation treatments.
- Combination Therapy Approaches
- Novel Treatment Strategies
- Therapeutic Innovation
The investigator explores treatment options that aim to improve patient outcomes in blood cancers.
Clinical Expertise
Specialization in treating high-risk hematologic conditions, including advanced myeloid disorders and complex blood cancers requiring intensive therapeutic intervention.
- Advanced Blood Disorders
- Complex Disease Management
- Treatment Optimization
The investigator's practice focuses on developing effective treatment strategies for challenging blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.